Home ›  Site Map

• About Lipoxen
  • Business Strategy
  • Directors
    • Sir Brian Richards, CBE, BSc, PhD, DSc
    • M Scott Maguire
    • Professor Gregory Gregoriadis PhD, DSc
    • Dr Dmitry D Genkin
    • Mr Colin William Hill, ACMA
    • Mr Firdaus Jal Dastoor, FCS
    • Mr Igor Nikolaev
  • Senior Management
    • Sir Brian Richards, CBE, BSc, PhD, DSc
    • M Scott Maguire
    • Professor Gregory Gregoriadis PhD, DSc
    • Dr Ajay K Agrawal PhD
    • Dr Sanjay Jain PhD
    • Andrew Bacon BSc
    • Dr Brenda McCormack PhD
    • Veronika Oswald
• Our Technologies
  • PolyXen®
    • Publications
  • ImuXen®
    • Publications
  • VesicALL®
• Pipeline
  • PolyXen® product pipeline
    • Polysialic EPO : ErepoXen®
    • Polysialic-GCSF : StimuXen™
    • Polysialic interferon-alpha-2b : InferoXen®
    • Polysialic Insulin (SuliXen®)
  • ImuXen® product pipeline
    • Liposomal Pneumococcal Vaccine : LipoNeu™
    • Oral Tetanus Vaccine : LipoTet™
    • Liposomal Hepatitis B vaccine : HepaXen™
    • Liposomal Rabies Vaccine : LipoRab™
  • VesicALL® product pipeline
    • Liposomal Paclitaxel : LipoTaxen™
• Partnering
• Corporate Governance
• Investor Centre
  • Share Information
  • Share price
  • Investor news
  • Advisors
  • Articles of Association
  • FAQS
    • How long has Lipoxen been listed as a public company
    • What is the size of the market for Lipoxen's products
    • What is the Company's ticker symbol
    • Who are the Company's registrars
    • On what exchange are the shares traded on
    • When does Lipoxen report results
    • What is the current share price of Lipoxen plc shares
  • Admission Document
• News
  • Lipoxen raises £2.6 million through Strategic Placing and Warrant Agreement with Serum Institute of India Limited
  • Development and Manufacturing Agreement with the Serum Institute of India Limited
  • Lipoxen Receives Bio Entrepreneur of the Year Award
  • Preliminary Results for the Year Ended 31 December 2005
  • Lipoxen Announces Positive Data for its ImuXen ® Liposomal Technology
  • Lipoxen Signs Intervet Agreement
  • Lipoxen's first clinical candidate, SuliXen, enters Phase I trials
  • Lipoxen Plc lists on AIM raising £3.78million
  • Change of Adviser
  • Lipoxen reports significant progress in the development of its DNA vaccine delivery patent portfolio
  • Lipoxen announces that its partner Serum Institute of India has begun Phase I trials of long-acting erythropoietin (EPO)
  • Sachs conference
  • Lipoxen Completes Technology Transfer for Sustained-Release Insulin
  • Lipoxen announces collaboration agreements with Baxter Healthcare & two other biopharmaceutical companies
  • News archive
  • Lipoxen Announces $75M Agreement with Baxter to Develop New Blood Clotting Factors
  • Lipoxen reports further advancement of its DNA vaccine delivery patent portfolio
  • Lipoxen Announces Positive Phase I ErepoXen Results
  • Lipoxen PLC Presenting at Sachs Associates
  • Lipoxen announces positive Phase I data with its long-acting insulin candidate, SuliXen
  • Lipoxen receives grant to research improved HIV vaccine delivery
  • Lipoxen has received approval to conduct the second Phase I trial
  • Canadian EPO Trial Correction
  • Financial Results for the 12 months ended 31 December 2007
  • Lipoxen Strengthens Management Team
  • Lipoxen to present at the SMi Drug Delivery Global Summit
  • Lipoxen to Develop Improved Delivery of Antiviral Drugs for the Treatment of Liver Disease caused by Hepatitis C
  • Lipoxen Signs Agreement with the Barbara Davis Center
  • Lipoxen announces Board Changes
  • Lipoxen enters into agreement to develop improved vaccines
  • Lipoxen Chief Scientific Officer, Professor Gregory Gregoriadis, Awarded Two Lifetime Achievement Honours
  • Lipoxen to Investigate the Development of Long-Acting GCSF
  • Interim Phase I Results - Long Acting EPO
  • Positive Data for Revolutionary Influenza Vaccine
  • Malaria Vaccine Agreements
  • New Evaluation Agreement Signed with Major Pharma Company
  • Lipoxen's Co-Delivery DNA Vaccine Patent Granted in EU and US
  • Notice of Annual General Meeting
  • Director Shareholding
  • Result of Annual General Meeting
  • Audit and Remuneration Committee Membership
  • Director/PDMR Shareholding
  • Additional Listing
  • Interim Results for the six months ended 30 June 2009
  • Lipoxen Appointed Lead for Vaccine Programme Grant
  • Senior Management Appointment
  • Scott Maguire, CEO of Lipoxen, talks to Proactive Investors
  • Additional listing and Total Voting Right
  • Lipoxen Additional listing
  • New Research Collaboration with Pharmsynthez
  • Patent Granted
  • Trading and Programme Update
  • European Patent Granted
• Careers
  • Current job opportunities
    • Postdoctoral Scientists: Polymer Medicines
  • Register your details
• FAQ
• Contact us